Brain Injury Antibody Profiling for Objective Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for brain injury, particularly mild traumatic brain injury, are subjective, lack precision, and do not provide timely, objective information, leading to potential misdiagnosis and inadequate treatment.
Innovation Solution
Utilizing antigen probe arrays to profile antibody responses to specific brain-related antigens, analyzing IgG and IgM reactivities, and employing machine learning algorithms to identify unique antigen-antibody reactivity patterns for accurate diagnosis and monitoring of brain injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (neurological examination, imaging techniques) are used, then diagnosis can be performed, but the diagnosis is subjective and lacks precision
Solution Approach 1:
The patent replaces subjective mechanical neurological examinations and imaging techniques with an automated biochemical detection system. The system uses antigen probe arrays to objectively measure antibody responses, substituting human judgment with quantitative biochemical data that provides both precision and reliability in diagnosing brain injury.
Solution Approach 2:
The patent introduces antibody responses to brain-related antigens as an intermediary marker. Instead of directly observing brain injury through unreliable subjective methods, the system measures the immune system's antibody response to specific antigens, which serves as an objective intermediary indicator of brain injury presence and severity.
2Loss of time
If current diagnostic procedures are used, then evaluation can be completed, but timely objective information is not provided
Solution Approach 1:
The patent performs preliminary biochemical profiling by measuring antibody responses to multiple brain-related antigens simultaneously using probe arrays. This preliminary action provides immediate objective information about brain injury status, eliminating the time delay associated with sequential subjective examinations and imaging procedures.
3Reliability
If imaging tests are performed routinely, then diagnostic coverage is improved, but health care costs increase
Solution Approach 1:
The patent applies partial action by using the antigen-antibody profiling method as a preliminary screening tool before ordering expensive imaging tests. This approach provides sufficient diagnostic information for many cases, reducing the number of unnecessary imaging procedures and associated costs while maintaining appropriate diagnostic coverage for cases that truly require imaging.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides highly specific, reliable, and discriminatory assays for diagnosing brain injury, reducing the need for unnecessary imaging tests and minimizing health care costs while ensuring timely and effective treatment.
Implementation Method 1
determining the reactivity of antibodies in the sample to at least one antigen selected from the group consisting of: SEQ ID NOs: 1-115, isoforms thereof, post-translationally modified forms thereof, fragments thereof; or combinations of any of the foregoing
Data Source
AI summary
Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.